Table of Content

1 Peripherally Acting Anti-Obesity Drug Market Overview
1.1 Product Overview and Scope of Peripherally Acting Anti-Obesity Drug
1.2 Peripherally Acting Anti-Obesity Drug Segment by Type
1.2.1 Global Peripherally Acting Anti-Obesity Drug Market Value Comparison by Type (2024-2034)
1.2.2 Prescription Drugs
1.2.3 Non-prescription Drugs
1.3 Peripherally Acting Anti-Obesity Drug Segment by Application
1.3.1 Global Peripherally Acting Anti-Obesity Drug Market Value by Application: (2024-2034)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global Peripherally Acting Anti-Obesity Drug Market Size Estimates and Forecasts
1.4.1 Global Peripherally Acting Anti-Obesity Drug Revenue 2024-2034
1.4.2 Global Peripherally Acting Anti-Obesity Drug Sales 2024-2034
1.4.3 Global Peripherally Acting Anti-Obesity Drug Market Average Price (2024-2034)
1.5 Assumptions and Limitations
2 Peripherally Acting Anti-Obesity Drug Market Competition by Manufacturers
2.1 Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Manufacturers (2024-2024)
2.2 Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Manufacturers (2024-2024)
2.3 Global Peripherally Acting Anti-Obesity Drug Average Price by Manufacturers (2024-2024)
2.4 Global Peripherally Acting Anti-Obesity Drug Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Peripherally Acting Anti-Obesity Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Peripherally Acting Anti-Obesity Drug, Product Type & Application
2.7 Peripherally Acting Anti-Obesity Drug Market Competitive Situation and Trends
2.7.1 Peripherally Acting Anti-Obesity Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Peripherally Acting Anti-Obesity Drug Players Market Share by Revenue
2.7.3 Global Peripherally Acting Anti-Obesity Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Peripherally Acting Anti-Obesity Drug Retrospective Market Scenario by Region
3.1 Global Peripherally Acting Anti-Obesity Drug Market Size by Region: 2024 Versus 2022 Versus 2034
3.2 Global Peripherally Acting Anti-Obesity Drug Global Peripherally Acting Anti-Obesity Drug Sales by Region: 2024-2034
3.2.1 Global Peripherally Acting Anti-Obesity Drug Sales by Region: 2024-2024
3.2.2 Global Peripherally Acting Anti-Obesity Drug Sales by Region: 2024-2034
3.3 Global Peripherally Acting Anti-Obesity Drug Global Peripherally Acting Anti-Obesity Drug Revenue by Region: 2024-2034
3.3.1 Global Peripherally Acting Anti-Obesity Drug Revenue by Region: 2024-2024
3.3.2 Global Peripherally Acting Anti-Obesity Drug Revenue by Region: 2024-2034
3.4 North America Peripherally Acting Anti-Obesity Drug Market Facts & Figures by Country
3.4.1 North America Peripherally Acting Anti-Obesity Drug Market Size by Country: 2024 VS 2022 VS 2034
3.4.2 North America Peripherally Acting Anti-Obesity Drug Sales by Country (2024-2034)
3.4.3 North America Peripherally Acting Anti-Obesity Drug Revenue by Country (2024-2034)
3.4.4 United States
3.4.5 Canada
3.5 Europe Peripherally Acting Anti-Obesity Drug Market Facts & Figures by Country
3.5.1 Europe Peripherally Acting Anti-Obesity Drug Market Size by Country: 2024 VS 2022 VS 2034
3.5.2 Europe Peripherally Acting Anti-Obesity Drug Sales by Country (2024-2034)
3.5.3 Europe Peripherally Acting Anti-Obesity Drug Revenue by Country (2024-2034)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Peripherally Acting Anti-Obesity Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Peripherally Acting Anti-Obesity Drug Market Size by Country: 2024 VS 2022 VS 2034
3.6.2 Asia Pacific Peripherally Acting Anti-Obesity Drug Sales by Country (2024-2034)
3.6.3 Asia Pacific Peripherally Acting Anti-Obesity Drug Revenue by Country (2024-2034)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Peripherally Acting Anti-Obesity Drug Market Facts & Figures by Country
3.7.1 Latin America Peripherally Acting Anti-Obesity Drug Market Size by Country: 2024 VS 2022 VS 2034
3.7.2 Latin America Peripherally Acting Anti-Obesity Drug Sales by Country (2024-2034)
3.7.3 Latin America Peripherally Acting Anti-Obesity Drug Revenue by Country (2024-2034)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Peripherally Acting Anti-Obesity Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Peripherally Acting Anti-Obesity Drug Market Size by Country: 2024 VS 2022 VS 2034
3.8.2 Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales by Country (2024-2034)
3.8.3 Middle East and Africa Peripherally Acting Anti-Obesity Drug Revenue by Country (2024-2034)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Peripherally Acting Anti-Obesity Drug Sales by Type (2024-2034)
4.1.1 Global Peripherally Acting Anti-Obesity Drug Sales by Type (2024-2024)
4.1.2 Global Peripherally Acting Anti-Obesity Drug Sales by Type (2024-2034)
4.1.3 Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Type (2024-2034)
4.2 Global Peripherally Acting Anti-Obesity Drug Revenue by Type (2024-2034)
4.2.1 Global Peripherally Acting Anti-Obesity Drug Revenue by Type (2024-2024)
4.2.2 Global Peripherally Acting Anti-Obesity Drug Revenue by Type (2024-2034)
4.2.3 Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Type (2024-2034)
4.3 Global Peripherally Acting Anti-Obesity Drug Price by Type (2024-2034)
5 Segment by Application
5.1 Global Peripherally Acting Anti-Obesity Drug Sales by Application (2024-2034)
5.1.1 Global Peripherally Acting Anti-Obesity Drug Sales by Application (2024-2024)
5.1.2 Global Peripherally Acting Anti-Obesity Drug Sales by Application (2024-2034)
5.1.3 Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Application (2024-2034)
5.2 Global Peripherally Acting Anti-Obesity Drug Revenue by Application (2024-2034)
5.2.1 Global Peripherally Acting Anti-Obesity Drug Revenue by Application (2024-2024)
5.2.2 Global Peripherally Acting Anti-Obesity Drug Revenue by Application (2024-2034)
5.2.3 Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Application (2024-2034)
5.3 Global Peripherally Acting Anti-Obesity Drug Price by Application (2024-2034)
6 Key Companies Profiled
6.1 Novo Nordisk A/S
6.1.1 Novo Nordisk A/S Corporation Information
6.1.2 Novo Nordisk A/S Description and Business Overview
6.1.3 Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Sales, Revenue and Gross Margin (2024-2024)
6.1.4 Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Product Portfolio
6.1.5 Novo Nordisk A/S Recent Developments/Updates
6.2 Pfizer Inc.
6.2.1 Pfizer Inc. Corporation Information
6.2.2 Pfizer Inc. Description and Business Overview
6.2.3 Pfizer Inc. Peripherally Acting Anti-Obesity Drug Sales, Revenue and Gross Margin (2024-2024)
6.2.4 Pfizer Inc. Peripherally Acting Anti-Obesity Drug Product Portfolio
6.2.5 Pfizer Inc. Recent Developments/Updates
6.3 Boehringer Ingelheim International GmbH
6.3.1 Boehringer Ingelheim International GmbH Corporation Information
6.3.2 Boehringer Ingelheim International GmbH Description and Business Overview
6.3.3 Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Sales, Revenue and Gross Margin (2024-2024)
6.3.4 Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Product Portfolio
6.3.5 Boehringer Ingelheim International GmbH Recent Developments/Updates
6.4 KVK Tech Inc.
6.4.1 KVK Tech Inc. Corporation Information
6.4.2 KVK Tech Inc. Description and Business Overview
6.4.3 KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Sales, Revenue and Gross Margin (2024-2024)
6.4.4 KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Product Portfolio
6.4.5 KVK Tech Inc. Recent Developments/Updates
6.5 Gelesis Holdings
6.5.1 Gelesis Holdings Corporation Information
6.5.2 Gelesis Holdings Description and Business Overview
6.5.3 Gelesis Holdings Peripherally Acting Anti-Obesity Drug Sales, Revenue and Gross Margin (2024-2024)
6.5.4 Gelesis Holdings Peripherally Acting Anti-Obesity Drug Product Portfolio
6.5.5 Gelesis Holdings Recent Developments/Updates
6.6 Vivus LLC.
6.6.1 Vivus LLC. Corporation Information
6.6.2 Vivus LLC. Description and Business Overview
6.6.3 Vivus LLC. Peripherally Acting Anti-Obesity Drug Sales, Revenue and Gross Margin (2024-2024)
6.6.4 Vivus LLC. Peripherally Acting Anti-Obesity Drug Product Portfolio
6.6.5 Vivus LLC. Recent Developments/Updates
6.7 Currax Pharmaceuticals LLC
6.6.1 Currax Pharmaceuticals LLC Corporation Information
6.6.2 Currax Pharmaceuticals LLC Description and Business Overview
6.6.3 Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Sales, Revenue and Gross Margin (2024-2024)
6.4.4 Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Product Portfolio
6.7.5 Currax Pharmaceuticals LLC Recent Developments/Updates
6.8 GlaxoSmithKline plc
6.8.1 GlaxoSmithKline plc Corporation Information
6.8.2 GlaxoSmithKline plc Description and Business Overview
6.8.3 GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Sales, Revenue and Gross Margin (2024-2024)
6.8.4 GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Product Portfolio
6.8.5 GlaxoSmithKline plc Recent Developments/Updates
6.9 CHEPLAPHARM Arzneimittel GmbH
6.9.1 CHEPLAPHARM Arzneimittel GmbH Corporation Information
6.9.2 CHEPLAPHARM Arzneimittel GmbH Description and Business Overview
6.9.3 CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Sales, Revenue and Gross Margin (2024-2024)
6.9.4 CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Product Portfolio
6.9.5 CHEPLAPHARM Arzneimittel GmbH Recent Developments/Updates
6.10 Rhythm Pharmaceuticals
6.10.1 Rhythm Pharmaceuticals Corporation Information
6.10.2 Rhythm Pharmaceuticals Description and Business Overview
6.10.3 Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Sales, Revenue and Gross Margin (2024-2024)
6.10.4 Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Product Portfolio
6.10.5 Rhythm Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Peripherally Acting Anti-Obesity Drug Industry Chain Analysis
7.2 Peripherally Acting Anti-Obesity Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Peripherally Acting Anti-Obesity Drug Production Mode & Process
7.4 Peripherally Acting Anti-Obesity Drug Sales and Marketing
7.4.1 Peripherally Acting Anti-Obesity Drug Sales Channels
7.4.2 Peripherally Acting Anti-Obesity Drug Distributors
7.5 Peripherally Acting Anti-Obesity Drug Customers
8 Peripherally Acting Anti-Obesity Drug Market Dynamics
8.1 Peripherally Acting Anti-Obesity Drug Industry Trends
8.2 Peripherally Acting Anti-Obesity Drug Market Drivers
8.3 Peripherally Acting Anti-Obesity Drug Market Challenges
8.4 Peripherally Acting Anti-Obesity Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Peripherally Acting Anti-Obesity Drug Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Peripherally Acting Anti-Obesity Drug Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Peripherally Acting Anti-Obesity Drug Market Competitive Situation by Manufacturers in 2022
Table 4. Global Peripherally Acting Anti-Obesity Drug Sales (K Units) of Key Manufacturers (2024-2024)
Table 5. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Manufacturers (2024-2024)
Table 6. Global Peripherally Acting Anti-Obesity Drug Revenue (US$ Million) by Manufacturers (2024-2024)
Table 7. Global Peripherally Acting Anti-Obesity Drug Revenue Share by Manufacturers (2024-2024)
Table 8. Global Market Peripherally Acting Anti-Obesity Drug Average Price (US$/Unit) of Key Manufacturers (2024-2024)
Table 9. Global Key Players of Peripherally Acting Anti-Obesity Drug, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Peripherally Acting Anti-Obesity Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Peripherally Acting Anti-Obesity Drug, Product Type & Application
Table 12. Global Key Manufacturers of Peripherally Acting Anti-Obesity Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Peripherally Acting Anti-Obesity Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peripherally Acting Anti-Obesity Drug as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Peripherally Acting Anti-Obesity Drug Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Table 17. Global Peripherally Acting Anti-Obesity Drug Sales by Region (2024-2024) & (K Units)
Table 18. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Region (2024-2024)
Table 19. Global Peripherally Acting Anti-Obesity Drug Sales by Region (2024-2034) & (K Units)
Table 20. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Region (2024-2034)
Table 21. Global Peripherally Acting Anti-Obesity Drug Revenue by Region (2024-2024) & (US$ Million)
Table 22. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Region (2024-2024)
Table 23. Global Peripherally Acting Anti-Obesity Drug Revenue by Region (2024-2034) & (US$ Million)
Table 24. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Region (2024-2034)
Table 25. North America Peripherally Acting Anti-Obesity Drug Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 26. North America Peripherally Acting Anti-Obesity Drug Sales by Country (2024-2024) & (K Units)
Table 27. North America Peripherally Acting Anti-Obesity Drug Sales by Country (2024-2034) & (K Units)
Table 28. North America Peripherally Acting Anti-Obesity Drug Revenue by Country (2024-2024) & (US$ Million)
Table 29. North America Peripherally Acting Anti-Obesity Drug Revenue by Country (2024-2034) & (US$ Million)
Table 30. Europe Peripherally Acting Anti-Obesity Drug Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 31. Europe Peripherally Acting Anti-Obesity Drug Sales by Country (2024-2024) & (K Units)
Table 32. Europe Peripherally Acting Anti-Obesity Drug Sales by Country (2024-2034) & (K Units)
Table 33. Europe Peripherally Acting Anti-Obesity Drug Revenue by Country (2024-2024) & (US$ Million)
Table 34. Europe Peripherally Acting Anti-Obesity Drug Revenue by Country (2024-2034) & (US$ Million)
Table 35. Asia Pacific Peripherally Acting Anti-Obesity Drug Revenue by Region: 2024 VS 2022 VS 2034 (US$ Million)
Table 36. Asia Pacific Peripherally Acting Anti-Obesity Drug Sales by Region (2024-2024) & (K Units)
Table 37. Asia Pacific Peripherally Acting Anti-Obesity Drug Sales by Region (2024-2034) & (K Units)
Table 38. Asia Pacific Peripherally Acting Anti-Obesity Drug Revenue by Region (2024-2024) & (US$ Million)
Table 39. Asia Pacific Peripherally Acting Anti-Obesity Drug Revenue by Region (2024-2034) & (US$ Million)
Table 40. Latin America Peripherally Acting Anti-Obesity Drug Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 41. Latin America Peripherally Acting Anti-Obesity Drug Sales by Country (2024-2024) & (K Units)
Table 42. Latin America Peripherally Acting Anti-Obesity Drug Sales by Country (2024-2034) & (K Units)
Table 43. Latin America Peripherally Acting Anti-Obesity Drug Revenue by Country (2024-2024) & (US$ Million)
Table 44. Latin America Peripherally Acting Anti-Obesity Drug Revenue by Country (2024-2034) & (US$ Million)
Table 45. Middle East & Africa Peripherally Acting Anti-Obesity Drug Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 46. Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales by Country (2024-2024) & (K Units)
Table 47. Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales by Country (2024-2034) & (K Units)
Table 48. Middle East & Africa Peripherally Acting Anti-Obesity Drug Revenue by Country (2024-2024) & (US$ Million)
Table 49. Middle East & Africa Peripherally Acting Anti-Obesity Drug Revenue by Country (2024-2034) & (US$ Million)
Table 50. Global Peripherally Acting Anti-Obesity Drug Sales (K Units) by Type (2024-2024)
Table 51. Global Peripherally Acting Anti-Obesity Drug Sales (K Units) by Type (2024-2034)
Table 52. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Type (2024-2024)
Table 53. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Type (2024-2034)
Table 54. Global Peripherally Acting Anti-Obesity Drug Revenue (US$ Million) by Type (2024-2024)
Table 55. Global Peripherally Acting Anti-Obesity Drug Revenue (US$ Million) by Type (2024-2034)
Table 56. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Type (2024-2024)
Table 57. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Type (2024-2034)
Table 58. Global Peripherally Acting Anti-Obesity Drug Price (US$/Unit) by Type (2024-2024)
Table 59. Global Peripherally Acting Anti-Obesity Drug Price (US$/Unit) by Type (2024-2034)
Table 60. Global Peripherally Acting Anti-Obesity Drug Sales (K Units) by Application (2024-2024)
Table 61. Global Peripherally Acting Anti-Obesity Drug Sales (K Units) by Application (2024-2034)
Table 62. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Application (2024-2024)
Table 63. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Application (2024-2034)
Table 64. Global Peripherally Acting Anti-Obesity Drug Revenue (US$ Million) by Application (2024-2024)
Table 65. Global Peripherally Acting Anti-Obesity Drug Revenue (US$ Million) by Application (2024-2034)
Table 66. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Application (2024-2024)
Table 67. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Application (2024-2034)
Table 68. Global Peripherally Acting Anti-Obesity Drug Price (US$/Unit) by Application (2024-2024)
Table 69. Global Peripherally Acting Anti-Obesity Drug Price (US$/Unit) by Application (2024-2034)
Table 70. Novo Nordisk A/S Corporation Information
Table 71. Novo Nordisk A/S Description and Business Overview
Table 72. Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 73. Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Product
Table 74. Novo Nordisk A/S Recent Developments/Updates
Table 75. Pfizer Inc. Corporation Information
Table 76. Pfizer Inc. Description and Business Overview
Table 77. Pfizer Inc. Peripherally Acting Anti-Obesity Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 78. Pfizer Inc. Peripherally Acting Anti-Obesity Drug Product
Table 79. Pfizer Inc. Recent Developments/Updates
Table 80. Boehringer Ingelheim International GmbH Corporation Information
Table 81. Boehringer Ingelheim International GmbH Description and Business Overview
Table 82. Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 83. Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Product
Table 84. Boehringer Ingelheim International GmbH Recent Developments/Updates
Table 85. KVK Tech Inc. Corporation Information
Table 86. KVK Tech Inc. Description and Business Overview
Table 87. KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 88. KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Product
Table 89. KVK Tech Inc. Recent Developments/Updates
Table 90. Gelesis Holdings Corporation Information
Table 91. Gelesis Holdings Description and Business Overview
Table 92. Gelesis Holdings Peripherally Acting Anti-Obesity Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 93. Gelesis Holdings Peripherally Acting Anti-Obesity Drug Product
Table 94. Gelesis Holdings Recent Developments/Updates
Table 95. Vivus LLC. Corporation Information
Table 96. Vivus LLC. Description and Business Overview
Table 97. Vivus LLC. Peripherally Acting Anti-Obesity Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 98. Vivus LLC. Peripherally Acting Anti-Obesity Drug Product
Table 99. Vivus LLC. Recent Developments/Updates
Table 100. Currax Pharmaceuticals LLC Corporation Information
Table 101. Currax Pharmaceuticals LLC Description and Business Overview
Table 102. Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 103. Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Product
Table 104. Currax Pharmaceuticals LLC Recent Developments/Updates
Table 105. GlaxoSmithKline plc Corporation Information
Table 106. GlaxoSmithKline plc Description and Business Overview
Table 107. GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 108. GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Product
Table 109. GlaxoSmithKline plc Recent Developments/Updates
Table 110. CHEPLAPHARM Arzneimittel GmbH Corporation Information
Table 111. CHEPLAPHARM Arzneimittel GmbH Description and Business Overview
Table 112. CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 113. CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Product
Table 114. CHEPLAPHARM Arzneimittel GmbH Recent Developments/Updates
Table 115. Rhythm Pharmaceuticals Corporation Information
Table 116. Rhythm Pharmaceuticals Description and Business Overview
Table 117. Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 118. Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Product
Table 119. Rhythm Pharmaceuticals Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. Peripherally Acting Anti-Obesity Drug Distributors List
Table 123. Peripherally Acting Anti-Obesity Drug Customers List
Table 124. Peripherally Acting Anti-Obesity Drug Market Trends
Table 125. Peripherally Acting Anti-Obesity Drug Market Drivers
Table 126. Peripherally Acting Anti-Obesity Drug Market Challenges
Table 127. Peripherally Acting Anti-Obesity Drug Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Peripherally Acting Anti-Obesity Drug
Figure 2. Global Peripherally Acting Anti-Obesity Drug Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Peripherally Acting Anti-Obesity Drug Market Share by Type in 2022 & 2034
Figure 4. Prescription Drugs Product Picture
Figure 5. Non-prescription Drugs Product Picture
Figure 6. Global Peripherally Acting Anti-Obesity Drug Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 7. Global Peripherally Acting Anti-Obesity Drug Market Share by Application in 2022 & 2034
Figure 8. Hospital Pharmacies
Figure 9. Retail Pharmacies
Figure 10. Online Pharmacies
Figure 11. Global Peripherally Acting Anti-Obesity Drug Revenue, (US$ Million), 2024 VS 2022 VS 2034
Figure 12. Global Peripherally Acting Anti-Obesity Drug Market Size (2024-2034) & (US$ Million)
Figure 13. Global Peripherally Acting Anti-Obesity Drug Sales (2024-2034) & (K Units)
Figure 14. Global Peripherally Acting Anti-Obesity Drug Average Price (US$/Unit) & (2024-2034)
Figure 15. Peripherally Acting Anti-Obesity Drug Report Years Considered
Figure 16. Peripherally Acting Anti-Obesity Drug Sales Share by Manufacturers in 2022
Figure 17. Global Peripherally Acting Anti-Obesity Drug Revenue Share by Manufacturers in 2022
Figure 18. The Global 5 and 10 Largest Peripherally Acting Anti-Obesity Drug Players: Market Share by Revenue in 2022
Figure 19. Peripherally Acting Anti-Obesity Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024 VS 2022
Figure 20. Global Peripherally Acting Anti-Obesity Drug Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Figure 21. North America Peripherally Acting Anti-Obesity Drug Sales Market Share by Country (2024-2034)
Figure 22. North America Peripherally Acting Anti-Obesity Drug Revenue Market Share by Country (2024-2034)
Figure 23. United States Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 24. Canada Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 25. Europe Peripherally Acting Anti-Obesity Drug Sales Market Share by Country (2024-2034)
Figure 26. Europe Peripherally Acting Anti-Obesity Drug Revenue Market Share by Country (2024-2034)
Figure 27. Germany Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 28. France Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 29. U.K. Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 30. Italy Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 31. Russia Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 32. Asia Pacific Peripherally Acting Anti-Obesity Drug Sales Market Share by Region (2024-2034)
Figure 33. Asia Pacific Peripherally Acting Anti-Obesity Drug Revenue Market Share by Region (2024-2034)
Figure 34. China Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 35. Japan Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 36. South Korea Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 37. India Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 38. Australia Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 39. China Taiwan Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 40. Southeast Asia Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 41. Latin America Peripherally Acting Anti-Obesity Drug Sales Market Share by Country (2024-2034)
Figure 42. Latin America Peripherally Acting Anti-Obesity Drug Revenue Market Share by Country (2024-2034)
Figure 43. Mexico Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 44. Brazil Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 45. Argentina Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 46. Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales Market Share by Country (2024-2034)
Figure 47. Middle East & Africa Peripherally Acting Anti-Obesity Drug Revenue Market Share by Country (2024-2034)
Figure 48. Turkey Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 49. Saudi Arabia Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 50. UAE Peripherally Acting Anti-Obesity Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 51. Global Sales Market Share of Peripherally Acting Anti-Obesity Drug by Type (2024-2034)
Figure 52. Global Revenue Market Share of Peripherally Acting Anti-Obesity Drug by Type (2024-2034)
Figure 53. Global Peripherally Acting Anti-Obesity Drug Price (US$/Unit) by Type (2024-2034)
Figure 54. Global Sales Market Share of Peripherally Acting Anti-Obesity Drug by Application (2024-2034)
Figure 55. Global Revenue Market Share of Peripherally Acting Anti-Obesity Drug by Application (2024-2034)
Figure 56. Global Peripherally Acting Anti-Obesity Drug Price (US$/Unit) by Application (2024-2034)
Figure 57. Peripherally Acting Anti-Obesity Drug Value Chain
Figure 58. Peripherally Acting Anti-Obesity Drug Production Process
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Distributors Profiles
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed